Brexafemme Approved For Recurrent Yeast Infections
The Food and Drug Administration (FDA) has approved Brexafemme for a second indication for reduction in incidence of recurrent vulvovaginal candidiasis, Scynexis announced Thursday “Brexafemme was already the…